

IN THE CLAIMS:

1. (Canceled).

2. (Previously Amended) The pharmaceutical composition according to claim
~~6~~, wherein the neuropathic pain is induced by diabetes or compression of nerves.

B1
3. (Previously Amended) The pharmaceutical composition according to claim
~~2~~, wherein the neuropathic pain is induced by diabetes.

4. (Previously Amended) The pharmaceutical composition according to claim
~~6~~, wherein the systemic administration method is oral administration.

5. (Canceled).

1
~~6~~. (Previously Amended) A pharmaceutical composition for use in treating
neuropathic pain, which is administered by a systemic method of administration and which
comprises a compound having mGluR1 antagonistic activity, wherein the compound having
mGluR1 antagonism is a compound selected from 6-amino-N-cyclohexyl-N,3-
dimethylthiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride and (+)-(1*R*,2*S*)-6-
amino-N-methyl-N-(2-methylcyclohexyl)thiazolo[3,2-a]benzoimidazole-2-carboxamide
dihydrochloride.

7-11 (Canceled).